Cited by 605CAR-T cell therapy researchCancer Immunotherapy and BiomarkersOccupational and environmental lung diseases

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Open access

Adusumilli, Prasad S., Zauderer, Marjorie G., Rivière, Isabelle, Solomon, Stephen B., Rusch, Valerie W., O'Cearbhaill, Roisin E., Zhu, Amy, Cheema, Waseem, Chintala, Navin K., Halton, Elizabeth, Pineda, John, Perez-Johnston, Rocio, Tan, Kay See, Daly, Bobby, Araujo Filho, Jose A., Ngai, Daniel, McGee, Erin, Vincent, Alain, Diamonte, Claudia, Sauter, Jennifer L., Modi, Shanu, Sikder, Devanjan, Senechal, Brigitte, Wang, Xiuyan, Travis, William D., Gönen, Mithat, Rudin, Charles M., Brentjens, Renier J., Jones, David R., Sadelain, Michel·2021·Cancer Discovery

DOI 10.1158/2159-8290.cd-21-0407PMC PMC8563385

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous, mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Intrapleural administration of 0.3M to 60M CAR T cells/kg in 27 patients (25 with MPM) was safe and well tolerated. CAR T cells were detected in peripheral blood for >100 days in 39% of patients. Following our demonstration that PD-1 blockade enhances CAR T-cell function in mice, 18 patients with MPM also received pembrolizumab safely. Among those patients, median overall survival from CAR T-cell infusion was 23.9 months (1-year overall survival, 83%). Stable disease was sustained for ≥6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors. Significance: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0407

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citation
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,098
Self-citation
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,062
Self-citation
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Self-citation
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Self-citation

Show all 37 references

Sorted by citations

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 695
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Flugel, C., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou‐El‐Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 586
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Narayan, V., Barber-Rotenberg, J. S., Jung, I.-Y., Lacey, S. F., Rech, A. J., Suhoski, M. M., Hwang, W., Lal, P., Carpenter, E. L., Maude, S. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01726-1 · Cited by 566
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. Μ. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 561
Immunotherapy: Reshape the Tumor Immune Microenvironment
Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 500
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 443
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
Gumber, D., & Wang, L. D. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 417
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
Philipp, N., Pasikhani, M. K., Nicholls, A., Vick, B., Wulf, J., Straub, T., Scheurer, M., Muth, A., Hänel, G., Nixdorf, D., et al. (2022) · Blood · doi:10.1182/blood.2022015956 · Cited by 289
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 284
Engineered cellular immunotherapies in cancer and beyond
Finck, A., Blanchard, T., Roselle, C., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 277
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Sloas, D. C., Gill, S. I., & Klichinsky, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783305 · Cited by 246
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Monje, M., Mahdi, J., Majzner, R. G., Yeom, K. W., Schultz, L. M., Richards, R. M., Barsan, V. V., Song, K.-W., Kamens, J. L., Baggott, C., et al. (2024) · Nature · doi:10.1038/s41586-024-08171-9 · Cited by 248
CAR-T: What Is Next?
Chen, Y., Abila, B., & Kamel, Y. M. (2023) · Cancers · doi:10.3390/cancers15030663 · Cited by 251
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Qi, C., Liu, C., Gong, J., Liu, D., Wang, X., Zhang, P., Qin, Y., Ge, S., Zhang, M., Peng, Z., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03037-z · Cited by 235
Self-citation
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Sorkhabi, A. D., Khosroshahi, L. M., Sarkesh, A., Mardi, A., Aghebati‐Maleki, A., Maleki, L. A., & Baradaran, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113882 · Cited by 219
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
Bagley, S. J., Binder, Z. A., Lamrani, L., Marinari, E., Desai, A. S., Nasrallah, M. P., Maloney, E., Brem, S. S., Lustig, R. A., Kurtz, G. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00709-6 · Cited by 199
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Agarwal, S., Aznar, M. A., Rech, A. J., Good, C. R., Kuramitsu, S., Da, T., Gohil, M., Chen, L., Hong, S.-J. A., Ravikumar, P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.001 · Cited by 199
Next-Generation CAR T-cell Therapies
Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., & June, C. H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1683 · Cited by 191
Beyond the blood: expanding CAR T cell therapy to solid tumors
Uslu, U., & June, C. H. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02446-2 · Cited by 190
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 170
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 163
Exhaustion of CAR T cells: potential causes and solutions
Kouro, T., Himuro, H., & Sasada, T. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03442-3 · Cited by 156
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
Dorff, T. B., Blanchard, M. S., Adkins, L. N., Luebbert, L., Leggett, N. A., Shishido, S. N., Macias, A., Real, M. M. D., Dhapola, G., Egelston, C. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02979-8 · Cited by 147
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 146
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 144
CAR T cell therapy in solid tumors: A review of current clinical trials
Patel, U., Abernathy, J., Savani, B. N., Oluwole, O. O., Sengsayadeth, S. M., & Dholaria, B. (2021) · eJHaem · doi:10.1002/jha2.356 · Cited by 133
CAR T cell combination therapies to treat cancer
Uslu, U., Castelli, S., & June, C. H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.07.002 · Cited by 129
PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
Yamaguchi, Y., Gibson, J., Ou, K., Lopez, L. S., Ng, R. H., Leggett, N. A., Jönsson, V. D., Zarif, J. C., Lee, P. P., Wang, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004400 · Cited by 136
Self-citation
Advancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 130
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Wehrli, M., Guinn, S. R., Birocchi, F., Kuo, A., Sun, Y., Larson, R. C., Almazan, A. J., Scarfò, I., Bouffard, A. A., Bailey, S. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3841 · Cited by 134
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Ghisoni, E., Morotti, M., Sarivalasis, A., Grimm, A. J., Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00937-4 · Cited by 131
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 129
Self-citation
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
Gottschlich, A., Thomas, M., Grünmeier, R., Lesch, S., Rohrbacher, L., Igl, V., Briukhovetska, D., Benmebarek, M.-R., Vick, B., Dede, S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01684-0 · Cited by 123
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
Lee, E. H. J., Murad, J. P., Christian, L., Gibson, J., Yamaguchi, Y., Cullen, C., Gumber, D., Park, A. K., Young, C. A., Monroy, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40115-1 · Cited by 121
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
Hassan, R., Butler, M. O., O'Cearbhaill, R. E., Oh, D. Y., Johnson, M. L., Zikaras, K., Smalley, M., Ross, M. G., Tanyi, J. L., Ghafoor, A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02452-y · Cited by 123
Self-citation
Adoptive cell therapy for cancer treatment
Du, S., Yan, J., Xue, Y., Zhong, Y., & Dong, Y. (2023) · Exploration · doi:10.1002/exp.20210058 · Cited by 123
Engineered T cell therapy for viral and non-viral epithelial cancers
Norberg, S. M., & Hinrichs, C. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.016 · Cited by 108
T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
Meyran, D., Zhu, J. J., Butler, J., Tantalo, D. G. M., Macdonald, S., Nguyen, T. N., Wang, M., Thio, N., D’Souza, C., Qin, V. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abk1900 · Cited by 108
The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better
Mao, R., Kong, W., & He, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032403 · Cited by 110
Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology
Tao, R., Han, X., Bai, X., Yu, J., Ma, Y.-W., Chen, W., Zhang, D., & Li, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354825 · Cited by 109
CAR-T cells in solid tumors: Challenges and breakthroughs
Escobar, G., Berger, T. R., & Maus, M. V. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102353 · Cited by 114
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells
Haas, A. R., Golden, R. J., Litzky, L. A., Engels, B., Zhao, L., Xu, F., Taraszka, J. A., Ramones, M., Granda, B. W., Chang, W., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.006 · Cited by 103
3D cancer models: One step closer to in vitro human studies
Manduca, N., Maccafeo, E., Maria, R. D., Sistigu, A., & Musella, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175503 · Cited by 103
The next generation of immunotherapies for lung cancers
Zhao, S., Zhao, H., Yang, W., & Zhang, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01035-9 · Cited by 96
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Li, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 95
Recent Advances in CAR-Based Solid Tumor Immunotherapy
Shin, M. H., Oh, E., Kim, Y. J., Nam, D.-H., Jeon, S., Yu, J. H., & Minn, D. (2023) · Cells · doi:10.3390/cells12121606 · Cited by 86
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
Andreu-Saumell, I., Rodríguez-García, A., Mühlgrabner, V., Giménez-Alejandre, M., Marzal, B., Castellsagué, J., Brasó‐Maristany, F., Calderón, H., Angelats, L., Colell, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47799-z · Cited by 87
Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
Dabas, P., & Danda, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02146-y · Cited by 86
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 84
Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors
Cherkassky, L., Hou, Z., Amador-Molina, A., & Adusumilli, P. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.006 · Cited by 77
Self-citation
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
Miao, L., Zhang, J., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840956 · Cited by 76
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., & Zhou, D. (2023) · Cancers · doi:10.3390/cancers15133476 · Cited by 75
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 73
PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion
Ouyang, W., Jin, S., Xu, N., Liu, W.-Y., Zhao, H. Q., Zhang, L., Kang, L., Tao, Y., Liu, Y., Wang, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008429 · Cited by 71
Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models
Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 70
Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study
Hu, Y., Zu, C., Zhang, M., Wei, G., Li, W., Fu, S., Hong, R., Zhou, L., Wu, W., Cui, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102010 · Cited by 68
Locoregional delivery of CAR-T cells in the clinic
Sagnella, S. M., White, A. L., Yeo, D., Saxena, P., van Zandwijk, N., & Rasko, J. E. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106329 · Cited by 62
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
Das, S., Valton, J., Duchateau, P. N., & Poirot, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172681 · Cited by 65
Prospects and challenges of CAR-T cell therapy combined with ICIs
Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 62
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Wang, X., Yang, X., Yuan, X., Wang, W., & Wang, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00341-7 · Cited by 60
Self-citation
Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
Schoutrop, E., Poiret, T., Serafi, I. E., Zhao, Y. H., He, R., Moter, A., Henriksson, J., Hassan, M., Magalhaes, I., & Mattsson, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005691 · Cited by 60
Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
Jilani, S., Saco, J. D., Mugarza, E., Pujol-Morcillo, A., Chokry, J., Ng, C., Abril-Rodríguez, G., Berger-Manerio, D., Pant, A., Hu, J. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45221-2 · Cited by 60
Oncolytic virus and CAR-T cell therapy in solid tumors
Ponterio, E., Haas, T. L., & Maria, R. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1455163 · Cited by 59
Challenges of Anti-Mesothelin CAR-T-Cell Therapy
Zhai, X., Mao, L., Wu, M., Liu, J., & Yu, S. (2023) · Cancers · doi:10.3390/cancers15051357 · Cited by 59
The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors
Wang, L., Zhang, L., Dunmall, L. C., Wang, Y. Y., Fan, Z., Cheng, Z., & Wang, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216871 · Cited by 59
Future perspectives on engineered T cells for cancer
Posey, A. D., Young, R. M., & June, C. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.007 · Cited by 58
Immunotherapy approaches for malignant pleural mesothelioma
Fennell, D. A., Dulloo, S., & Harber, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00649-7 · Cited by 62
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Ghaedrahmati, F., Esmaeil, N., & Abbaspour, M. (2022) · 癌症：英文版 · doi:10.1002/cac2.12394 · Cited by 57
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives
Azeez, S. S., Yashooa, R. K., Smail, S., Salihi, A., Ali, A. S., Mamand, S., & Janson, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02386-8 · Cited by 56
Components, Formulations, Deliveries, and Combinations of Tumor Vaccines
Liu, T., Yao, W., Sun, W., Yuan, Y., Liu, C., Liu, X., Wang, X., & Jiang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c05065 · Cited by 57
Self-citation
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis
Ma, Q., He, X., Zhang, B., Guo, F., Ou, X., Yang, Q., Shu, P., Chen, Y., Li, K., Gao, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01198-2 · Cited by 55
Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
Liu, X., Onda, M., Watson, N., Hassan, R., Ho, M., Bera, T. K., Wei, J., Chakraborty, A., Beers, R., Zhou, Q., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202439119 · Cited by 54
Genetically engineered cellular nanoparticles for biomedical applications
Krishnan, N., Peng, F.-X., Mohapatra, A., Fang, R. H., & Zhang, L. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122065 · Cited by 56
Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?
Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 59
Immunosenescence, inflammaging, and cancer immunotherapy efficacy
Rodriguez, J. E., Naigeon, M., Goldschmidt, V., Dugage, M. R., Seknazi, L., Danlos, F., Champiat, S., Marabelle, A., Michot, J., Massard, C., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2098718 · Cited by 55
NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
Dezfouli, A. B., Yazdi, M., Pockley, A. G., Khosravi, M., Kobold, S., Wagner, E., & Multhoff, G. (2021) · Cells · doi:10.3390/cells10123390 · Cited by 53
Adoptive Cell Therapy for Nonhematologic Solid Tumors
Olson, D. J., & Odunsi, K. O. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01618 · Cited by 53
Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 51
Recent advances and remaining challenges in lung cancer therapy
Barr, T., Ma, S., Li, Z., & Yu, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002991 · Cited by 52
Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions
Sheth, R. A., Wehrenberg-Klee, E. P., Patel, S. P., Brock, K. K., Fotiadis, N., & de Baère, T. (2024) · Radiology · doi:10.1148/radiol.232654 · Cited by 51
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
Tomar, S., Zhang, J., Khanal, M., Hong, J., Venugopalan, A. K., Jiang, Q., Sengupta, M., Miettinen, M., Li, N., Pastan, I. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0073 · Cited by 50
Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma
Yang, C., You, J., Pan, Q., Tang, Y., Cai, L., Huang, Y., Gu, J., Wang, Y., Yang, X., Du, Y., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03016-0 · Cited by 48
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers
Gu, X., Zhang, Y., Zhou, W., Wang, F., Yan, F., Gao, H., & Wang, W. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00542-2 · Cited by 49
ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights
Ali, A. M., & DiPersio, J. F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1432799 · Cited by 50
Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
Harber, J., Kamata, T., Pritchard, C. A., & Fennell, D. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003032 · Cited by 47
A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy
Mei, Y., Tang, L., Zhang, L., Hu, J., Zhang, Z., He, S., Zang, J., & Wang, W. (2022) · Materials Today · doi:10.1016/j.mattod.2022.09.009 · Cited by 47
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
Olivera, I., Bolaños, E., González-Gomariz, J., Hervás‐Stubbs, S., Mariño, K. V., Luri‐Rey, C., Etxeberría, I., Cirella, A., Egea, J., Glez‐Vaz, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100978 · Cited by 46
CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar
Chen, K., Liu, M., Wang, J., & Fang, S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9675 · Cited by 49
Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling
Bell, M. R., Lange, S., Sejdiu, B. I., Ibañez-Vega, J., Shi, H., Sun, X., Meng, X., Nguyen, P., Sutton, M. T., Wagner, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01143-w · Cited by 45
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
Schoutrop, E., Renken, S., Nilsson, I. M., Hahn, P., Poiret, T., Kiessling, R. W., Wickström, S. L., Mattsson, J., & Magalhaes, I. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2093426 · Cited by 44
CRISPR-Cas System: The Current and Emerging Translational Landscape
Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 46
Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis
Zhu, H., Yang, S.-H., Gao, C., Bian, Z.-H., Chen, X.-M., Huang, R., Meng, Q.-L., Li, X., Jin, H., Tsuneyama, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46654-5 · Cited by 43
Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer
Li, Y., Sharma, A., & Schmidt‐Wolf, I. G. H. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01926-4 · Cited by 48
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 44
Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors
Hong, M., Talluri, S., & Chen, Y. Y. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103020 · Cited by 42

Authors: Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., Pineda, J., Perez-Johnston, R., Tan, K. S., Daly, B., Araujo Filho, J. A., Ngai, D., McGee, E., Vincent, A., Diamonte, C., Sauter, J. L., Modi, S., Sikder, D., Senechal, B., Wang, X., Travis, W. D., Gönen, M., Rudin, C. M., Brentjens, R. J., Jones, D. R., & Sadelain, M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
6Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
5Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Corresponding author: Adusumilli, Prasad S.
ORCID: Adusumilli, Prasad S.
Zauderer, Marjorie G.
Rivière, Isabelle
Solomon, Stephen B.
Rusch, Valerie W.
O'Cearbhaill, Roisin E.
Cheema, Waseem
Chintala, Navin K.
Pineda, John
Perez-Johnston, Rocio
Tan, Kay See
Daly, Bobby
Sauter, Jennifer L.
Modi, Shanu
Wang, Xiuyan
Travis, William D.
Gönen, Mithat
Rudin, Charles M.
Brentjens, Renier J.
Jones, David R.
Sadelain, Michel
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2021-07-15
Volume: 11
Issue: 11
Pages: 2748-2763
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-21-0407
PMC: PMC8563385
OpenAlex: W3179214161
Cited by: 605
References: 37
Citations by year: 2026: 124 · 2025: 119 · 2024: 131 · 2023: 125 · 2022: 90 · 2021: 15
FWCI: 32.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: NIH (P30 CA008748, R01 CA236615-01, R01 CA235667)
U.S. Department of Defense (BC132124, LC160212, CA180889)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords: mesothelin, chimeric antigen receptor T cells, CAR T-cell therapy, malignant pleural mesothelioma, malignant pleural effusion, pembrolizumab, anti-PD-1 therapy, intrapleural administration, combination immunotherapy, autologous T cells, safety and tolerability, overall survival
MeSH terms: Mesothelin, Humans, Mesothelioma, Pleural Diseases, Immunotherapy, Adoptive, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks